CA2346036A1 - Methodes de regulation de la formation osseuse - Google Patents

Methodes de regulation de la formation osseuse Download PDF

Info

Publication number
CA2346036A1
CA2346036A1 CA002346036A CA2346036A CA2346036A1 CA 2346036 A1 CA2346036 A1 CA 2346036A1 CA 002346036 A CA002346036 A CA 002346036A CA 2346036 A CA2346036 A CA 2346036A CA 2346036 A1 CA2346036 A1 CA 2346036A1
Authority
CA
Canada
Prior art keywords
cells
bone
mammal
apoptosis
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002346036A
Other languages
English (en)
Inventor
Shun-Ichi Harada
Mohamed Machwate
Gideon A. Rodan
Sevgi B. Rodan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9824574.9A external-priority patent/GB9824574D0/en
Application filed by Individual filed Critical Individual
Publication of CA2346036A1 publication Critical patent/CA2346036A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Cette invention a trait à des méthodes de régulation de la formation osseuse chez des mammifères consistant à leur administrer une quantité efficace du point de vue thérapeutique d'un inhibiteur de l'apoptose de cellules de lignée ostéoblastique.
CA002346036A 1998-10-15 1999-10-12 Methodes de regulation de la formation osseuse Abandoned CA2346036A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US10433898P 1998-10-15 1998-10-15
US60/104,338 1998-10-15
GB9824574.9 1998-11-09
GBGB9824574.9A GB9824574D0 (en) 1998-11-09 1998-11-09 Methods for regulating bone formation
PCT/US1999/023755 WO2000021523A1 (fr) 1998-10-15 1999-10-12 Methodes de regulation de la formation osseuse

Publications (1)

Publication Number Publication Date
CA2346036A1 true CA2346036A1 (fr) 2000-04-20

Family

ID=26314646

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002346036A Abandoned CA2346036A1 (fr) 1998-10-15 1999-10-12 Methodes de regulation de la formation osseuse

Country Status (5)

Country Link
EP (1) EP1121113A1 (fr)
JP (1) JP2002527386A (fr)
AU (1) AU1110600A (fr)
CA (1) CA2346036A1 (fr)
WO (1) WO2000021523A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6492170B1 (en) 2000-09-11 2002-12-10 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 9 expression
US6566135B1 (en) 2000-10-04 2003-05-20 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 6 expression
JP5080284B2 (ja) * 2006-02-10 2012-11-21 株式会社エリナ 骨疾患の予防及び／又は治療用医薬組成物、その組成物を含有する機能性食品、健康食品及び医薬製剤、並びに歯根−歯周組織形成促進剤
WO2011008052A2 (fr) * 2009-07-17 2011-01-20 한국생명공학연구원 Composition pour la prévention ou le traitement de maladies osseuses comprenant du daropate de colforsine
DE102014101862A1 (de) 2014-02-14 2015-08-20 Eberhard Karls Universität Tübingen Medizinische Fakultät Immortalisierte Zelle
EP3133149B1 (fr) 2014-04-18 2022-06-22 Kyoto Prefectural Public University Corporation Procédé de préparation d'ostéoblastes et d'un inducteur d'ostéoblastes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4782082A (en) * 1982-12-27 1988-11-01 Schering Corporation Method for treating allergic reactions with Forskolin
US5366965A (en) * 1993-01-29 1994-11-22 Boehringer Mannheim Gmbh Regimen for treatment or prophylaxis of osteoporosis
US5858778A (en) * 1996-12-27 1999-01-12 Thomas Jefferson University SF caspase-1 and compositions for making and methods of using the same

Also Published As

Publication number Publication date
WO2000021523A1 (fr) 2000-04-20
EP1121113A1 (fr) 2001-08-08
JP2002527386A (ja) 2002-08-27
AU1110600A (en) 2000-05-01

Similar Documents

Publication Publication Date Title
US7576053B2 (en) Methods and compositions for treating degenerative bone disorders
Henriksen et al. Four-month treatment with GLP-2 significantly increases hip BMD: a randomized, placebo-controlled, dose-ranging study in postmenopausal women with low BMD
US6416737B1 (en) Increasing bone strength with selected bisphosphonates
Takano-Yamamoto et al. Direct effects of 17 beta-estradiol on trabecular bone in ovariectomized rats.
Chesnut Iii et al. Salmon calcitonin: a review of current and future therapeutic indications
CA2346031A1 (fr) Methodes de stimulation de la formation osseuse
US20040235728A1 (en) Compositions and methods for treating osteoporosis
Zhang et al. Thyroid-stimulating hormone maintains bone mass and strength by suppressing osteoclast differentiation
Thomas Intermittent parathyroid hormone therapy to increase bone formation
EP1148877A1 (fr) Inhibition de la resorption osseuse
Frediani et al. Long-term effects of neridronate on human osteoblastic cell cultures
US20030109537A1 (en) Methods and materials for treating bone conditions
Gooi et al. Decline in calcitonin receptor expression in osteocytes with age
US6586457B2 (en) Methods for inhibiting bone resorption
Gowen et al. Emerging therapies for osteoporosis
Wezeman et al. Alendronate administration and skeletal response during chronic alcohol intake in the adolescent male rat
CA2346036A1 (fr) Methodes de regulation de la formation osseuse
US20020004495A1 (en) Methods for stimulating bone formation
Elkalawy et al. Collagen Hydrolysate Against Fluvoxamine Maleate-Induced Osteoporosis in Albino Rats: A Histological and Immunohistochemical Study
Li et al. Preadministration of incadronate disodium can prevent bone loss in rat proximal tibial metaphysis when induced by hindlimb immobilization by bandage
JP2003529365A (ja) ゲラニルゲラニルジホスフェートシンターゼを阻害するために有用な化合物の同定方法
Gegnas Patent focus on agents for osteoporosis: September 1999-February 2000
AU2002340367A1 (en) Compositions and methods for treating osteoporosis
Barbuto Parathyroid Hormone Regulates Osterix Promoter Activity In Vitro and Expression In Vivo
Matreja et al. Newer Approaches in the Treatment of Osteoporosis

Legal Events

Date Code Title Description
FZDE Discontinued